TY - JOUR
T1 - Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast
T2 - experience from a large academic center
AU - Shafi, Saba
AU - Hu, Yan
AU - Parwani, Anil V.
AU - Ding, Qingqing
AU - Li, Zaibo
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/12
Y1 - 2022/12
N2 - Purpose: The recent WHO classification of breast cancer (2019) categorizes breast carcinoma with neuroendocrine (NE) differentiation into three morphologically distinct subtypes: well-differentiated neuroendocrine tumor (NET), poorly differentiated neuroendocrine carcinoma (NEC), and invasive breast carcinoma, no special type with neuroendocrine differentiation (IBC-NST-NE). Data regarding the prognostic significance of neuroendocrine differentiation are conflicting and an association, if any, between p53 mutation and neuroendocrine differentiation is largely unknown. Methods: We examined p53 expression and other clinicopathologic characteristics in three types of invasive breast carcinoma with NE differentiation in a cohort of sixty-three patients, including 45 IBC-NST with NE differentiation, 10 NETs, and 8 NECs. Results: No significant difference of clinicopathologic feature was observed between IBC-NST with NE differentiation and NET, but NECs showed significantly lower expressions of hormone receptors, more mutated p53, and higher frequency of distant metastases than IBC-NST with NE differentiation and NETs. Conclusion: NECs of the breast are genetically and clinically different from IBC-NST-NEs and NETs of the breast.
AB - Purpose: The recent WHO classification of breast cancer (2019) categorizes breast carcinoma with neuroendocrine (NE) differentiation into three morphologically distinct subtypes: well-differentiated neuroendocrine tumor (NET), poorly differentiated neuroendocrine carcinoma (NEC), and invasive breast carcinoma, no special type with neuroendocrine differentiation (IBC-NST-NE). Data regarding the prognostic significance of neuroendocrine differentiation are conflicting and an association, if any, between p53 mutation and neuroendocrine differentiation is largely unknown. Methods: We examined p53 expression and other clinicopathologic characteristics in three types of invasive breast carcinoma with NE differentiation in a cohort of sixty-three patients, including 45 IBC-NST with NE differentiation, 10 NETs, and 8 NECs. Results: No significant difference of clinicopathologic feature was observed between IBC-NST with NE differentiation and NET, but NECs showed significantly lower expressions of hormone receptors, more mutated p53, and higher frequency of distant metastases than IBC-NST with NE differentiation and NETs. Conclusion: NECs of the breast are genetically and clinically different from IBC-NST-NEs and NETs of the breast.
KW - Breast cancer
KW - Neuroendocrine carcinoma
KW - Neuroendocrine neoplasm
KW - Neuroendocrine tumor
KW - p53
UR - http://www.scopus.com/inward/record.url?scp=85140101866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140101866&partnerID=8YFLogxK
U2 - 10.1007/s10549-022-06766-2
DO - 10.1007/s10549-022-06766-2
M3 - Article
C2 - 36260193
AN - SCOPUS:85140101866
SN - 0167-6806
VL - 196
SP - 463
EP - 469
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -